Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Hims & Hers Health ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the ...

One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. (NYSE: HIMS), not only due to its ...

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS), an ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...

According to Benzinga Pro, Hims & Hers Health's peer group average for short interest as a percentage of float is 8.31%, which means the company has more short interest than most of its peers. Did you ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision to end a partnership for Wegovy. Read more here.

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs. These drugs are ...